Market Overview

I think you’ll love what you hear,
what you’ll see and the opportunities
that will be set before you.
- Jon Najarian

Medidata Selected by ICON to Evolve Image Management and Accelerate Research Goals for Sponsors and Sites During Clinical Trials


Medidata Medical Imaging® Provides End-to-End Control of
Rapidly Growing Data Source

(NASDAQ:MDSO), the leading global provider of cloud-based solutions and
data analytics for clinical research, and ICON
(NASDAQ:ICLR), a global provider of drug development solutions and
services to the pharmaceutical, biotechnology and medical device
industries, today announced a new collaboration to enhance the
management of medical imaging during drug development research. ICON
will expand its use of the Medidata
Clinical Cloud
® to include image management services for end-to-end
digital control of the healthcare industry's fastest growing data source.

ICON, a Medidata CRO partner since 2005, will now leverage Medidata
Medical Imaging
® to manage imaging studies through a single, unified
cloud platform. With Medidata imaging technology, ICON customers,
including sponsors and sites, will have the added benefit of
configurable and near real-time image access; enhancing speed and
facilitating analysis during clinical trials.

"Imaging biomarkers have become a key element in clinical trial design
and are a valuable resource in enabling early decision making and
pipeline management," commented Paul McCracken, ICON's VP Imaging. "By
adding Medidata imaging to our market-leading expertise and suite of
technology assets, we are streamlining the management of images during
clinical trials, which will help to improve quality and reduce the cycle
times associated with medical image management."

Medidata Medical Imaging works seamlessly with the Medidata Clinical
Cloud or as a stand-alone solution, enabling efficient workflow
management and flexibility. The Medidata solution automates the
distribution and review process after the image upload; reducing the
time associated with image management, while increasing data quality and

"We are proud to be a long time partner of ICON, and our new
collaboration reinforces ICON's dedication to facilitating the discovery
of new patient solutions," said Wade Wirta, managing director, Medidata.
"Imaging technology is opening new doors during the drug development
process, from the monitoring of outcomes to therapy responses. With the
Medidata cloud platform, researchers can efficiently leverage imaging to
accelerate clinical trial breakthroughs."

About Medidata:
is reinventing global drug and medical device development by creating
the industry's leading cloud-based solutions for clinical research.
Through our advanced applications and intelligent data analytics,
Medidata helps advance the scientific goals of life sciences customers
worldwide, including over 950 global pharmaceutical companies, biotech,
diagnostic and device firms, leading academic medical centers, and
contract research organizations.

The Medidata Clinical Cloud® brings a new level of quality and
efficiency to clinical trials that empower our customers to make more
informed decisions earlier and faster. Our unparalleled clinical trial
data assets provide deep insights that pave the way for future growth.
The Medidata Clinical Cloud is the primary technology solution powering
clinical trials for 18 of the world's top 25 global pharmaceutical
companies and is used by 18 of the top 25 medical device developers—from
study design and planning through execution, management and reporting.

About ICON plc
ICON plc is a global provider of drug
development solutions and services
to the pharmaceutical, biotechnology and medical device industries. The
company specialises in the strategic development, management and
analysis of programs that support clinical development - from compound
selection to Phase I-IV clinical studies. With headquarters in Dublin,
Ireland, ICON currently, operates from 97 locations in 38 countries and
has approximately 13,100 employees. Further information is available at

View Comments and Join the Discussion!